Focused On-demand Library for Sorting nexin-10

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9Y5X0

UPID:

SNX10_HUMAN

Alternative names:

Alternative UPACC:

Q9Y5X0; E9PFH5; Q8IYT5

Background:

Sorting nexin-10, identified by the accession number Q9Y5X0, plays a pivotal role in protein sorting and membrane trafficking within endosomes. It is crucial for cilium biogenesis, regulating the transport and localization of specific proteins to the cilium, including V-ATPase subunits and RAB8A. This protein is also instrumental in osteoclast differentiation, impacting bone resorption.

Therapeutic significance:

Sorting nexin-10's involvement in osteopetrosis, autosomal recessive 8, underscores its therapeutic potential. The disease, characterized by dense bones and impaired osteoclast function, highlights the protein's critical role in bone resorption. Understanding the role of Sorting nexin-10 could open doors to potential therapeutic strategies for treating osteopetrosis and related bone density disorders.